Navigation Links
Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
Date:5/2/2012

SAN FRANCISCO, May 2, 2012 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the first quarter ended March 31, 2012.

Cash, cash equivalents, and investments at March 31, 2012 were $498.8 million as compared to $414.9 million at December 31, 2011.
This increase is primarily a result of the $124.0 million in proceeds received by Nektar for the sale of its Cimzia® and Mircera® royalty interests, which was completed during the first quarter of 2012.

"I am extremely pleased with Nektar's performance in the first quarter of 2012," said Howard W. Robin, President and Chief Executive Officer of Nektar. "We significantly strengthened our financial position with the sale of non-core royalties for $124 million with no equity dilution to our stockholders. We completed the Phase 1 clinical trials for NKTR-181, our novel opioid analgesic for chronic pain, and are targeting the start of the Phase 2 program in the middle of this year. In addition, we advanced our next new opioid candidate, NKTR-192 for acute pain, into Phase 1.  Finally, the FDA approved the eighth product enabled by Nektar technology, Affymax's OMONTYS® for anemia, showcasing the ability of our technology platform to continue to produce new product candidates in high value therapeutic areas."

The company also announced that the naloxegol clinical studies in opioid-induced constipation continue on-track for planned regulatory filings by AstraZeneca in mid-2013, and partner Baxter is targeting the start of Phase 3 development by year-end for BAX 855, a long-acting PEGylated Factor VIII therapeutic candidate for hemophilia A. 

Revenue for the first quarter of 2012 was $17.9 million, an increase versus $11.3 million in the first quarter of 2011. The increase was primarily due to higher product sales during the quarter.  T
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
2. Nektar Consolidates Research at Its State-of-the-Art R&D Center Located in San Francisco at Mission Bay
3. Nektar Therapeutics Reports Fourth Quarter and Year-End 2011 Financial Results
4. Nektar Therapeutics Announces Agreement to Sell CIMZIA® and MIRCERA® Royalties to Royalty Pharma for $124 Million
5. Nektar Presents Positive Proof-of-Concept Clinical Data for Its New Opioid Molecule, NKTR-181, at American Academy of Pain Medicines 28th Annual Meeting
6. Nektar to Announce Financial Results for the Fourth Quarter and Year-End of 2011 on Wednesday, February 29, 2012, After Close of U.S.-Based Financial Markets
7. Positive Data for Nektars New Mu-Opioid Analgesic Molecule to Treat Acute Pain Highlighted at Neuroscience 2011
8. Nektar Therapeutics Reports Third Quarter 2011 Financial Results
9. Nektar to Announce Financial Results for the Third Quarter of 2011 on Wednesday, November 2, 2011, After Close of U.S.-Based Financial Markets
10. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the UBS 2011 Global Life Sciences Conference in New York City
11. Nektar Initiates Second Phase 1 Clinical Study Evaluating NKTR-181, A Novel Opioid Molecule, for Treatment of Chronic Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 2014   Hospira, Inc. (NYSE: ... and infusion technologies, today announced that the company will ... on Wednesday, Jan. 14, 2015, in San Francisco.  ... at 10:30 a.m. Pacific time on Wednesday, Jan. 14, ... through a live audiocast accessible via the Investor Relations ...
(Date:12/19/2014)... CARDIFF-BY-THE-SEA, Calif. , Dec. 19, ... SRNE ;  Sorrento), an oncology company developing new ... Inc., a privately-held immuno-oncology company developing proprietary Neukoplast ... based therapy, announced today that the companies have ... next generation CAR-TNK™ (pronounced as "Car-Tank") immunotherapies for ...
(Date:12/19/2014)... , Dec. 18, 2014  Sage Analytics ( ... of equipment for the testing of marijuana potency ... the new Luminary™ Profiler, the industry,s first product ... in a cost-effective, portable unit. Designed ... needs of the cannabis industry, the Luminary™ Profiler ...
Breaking Medicine Technology:Sorrento and Conkwest Announce Exclusive Global Collaboration 2Sorrento and Conkwest Announce Exclusive Global Collaboration 3Sorrento and Conkwest Announce Exclusive Global Collaboration 4Sorrento and Conkwest Announce Exclusive Global Collaboration 5Sage Analytics Develops Breakthrough System for Potency Testing of Cannabis Products 2
... Pa., June 25, 2007 /PRNewswire-FirstCall/ --,Genaera Corporation ... of trodusquemine (MSI-1436) for the treatment of ... (ADA) 67th,Scientific Sessions, June 22-25 in Chicago, ... lead author of Abstract #1801-P,presented, "Trodusquemine is ...
... blood sugar reductions seen across range of,patient populations, ... high risk of developing diabetes , * Galvus ... efficacy in combination with commonly used diabetes,medicines , ... studies showing,incidence of side effects similar to placebo ...
Cached Medicine Technology:Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for,the Treatment of Obesity at the American Diabetes Association 67th,Scientific Session 2Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for,the Treatment of Obesity at the American Diabetes Association 67th,Scientific Session 3Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for,the Treatment of Obesity at the American Diabetes Association 67th,Scientific Session 4New Data from Multiple Studies Show Galvus Delivers Consistent and,Robust Blood Sugar Control in Patients with Type 2 Diabetes 2New Data from Multiple Studies Show Galvus Delivers Consistent and,Robust Blood Sugar Control in Patients with Type 2 Diabetes 3New Data from Multiple Studies Show Galvus Delivers Consistent and,Robust Blood Sugar Control in Patients with Type 2 Diabetes 4New Data from Multiple Studies Show Galvus Delivers Consistent and,Robust Blood Sugar Control in Patients with Type 2 Diabetes 5New Data from Multiple Studies Show Galvus Delivers Consistent and,Robust Blood Sugar Control in Patients with Type 2 Diabetes 6
(Date:12/21/2014)... California (PRWEB) December 21, 2014 Serious ... search for Vintage 1967 Jm Morrison and the Doors International ... posters. This would also be the only time that ... concert was on Nov. 25, 1967. According to Hawley, ... D.C. They did play the Alexandria Roller Rink earlier ...
(Date:12/21/2014)... 2014 Theme and plugin ... intro plugin for Final Cut Pro X entitled ProMotion. ... and more with absolute ease.” Said Christiana Austin, CEO ... tools needed to easily animate their media inside FCPX.” ... X users to animate pictures, videos, logos, and more ...
(Date:12/21/2014)... 2014 Concept Plus, LLC. a SDB ... in Fairfax, VA., today announced it has been recognized ... list, which ranks the fastest growing government contracting small businesses ... 2013. , This is the first year that Concept Plus, ... 20 with a 95.92% compound annual growth rate. “For Concept ...
(Date:12/20/2014)... Weddingshe.com has recently announced its new collection of sweet ... occasion dresses for the coming new year. , ... for global women. Now, all the models on its ... off. Among the new items, the model of 10986064 ... very popular. What’s more, Weddingshe.com also provides a fast ...
(Date:12/20/2014)... (PRWEB) December 20, 2014 The print ... Post, with a distribution of approximately 160,000 copies and ... distributed nationally through a vast social media strategy and ... outlets. To explore the digital version of the campaign, ... exclusive interview with the ladies of CTV’s The ...
Breaking Medicine News(10 mins):Health News:Announcing a new plugin for Final Cut Pro X ProMotion from Pixel Film Studios. 2Health News:Concept Plus, LLC. Named One of Washington Technology’s Fast 50 2Health News:Tons of New-in Winter Sweet 16 Dresses from Weddingshe Online Now 2Health News:The ladies of The Social urge Canadian women to put themselves first over the holiday season and into the new year in Mediaplanet’s “Women’s Health” campaign 2
... Eularis, will be delivering a MasterClass on how to tell if you are making ... WHAT: MasterClass on the latest techniques, strategies and analysis, ... measure financial impact of sales, ... WHERE: 1 Northumberland Avenue, Trafalgar Square. London, , ...
... economic conditions and the unknown effect of healthcare ... Milliman, Inc., one of the premier global ... total medical spending for its "typical American family ... While cost trends are decelerating for the third-straight ...
... Calif., May 18 Fate Therapeutics, Inc. ... the Company,s executive team with the addition of Pratik ... With more than a decade of clinical development ... trials of Stem Cell Modulators (SCMs), small molecules and ...
... show promise for better protection against flu , , MONDAY, ... virus-like particles (VLPs) could provide stronger and longer-lasting protection ... Even better, VLP vaccines, which can be grown in ... twice as quickly as conventional vaccines, according to research ...
... about vaginal dryness and pain and are reluctant to ... international survey presented today at the European Congress on ... over a third (39 percent) of post-menopausal women experience ... women who have recently experienced vaginal dryness and pain ...
... in Clinical Trials and Population Health MonitoringLINCOLN, R.I., May 18 ... well-being as a good night,s sleep. Yet millions of us ... -- suffer from chronic sleep problems or disorders. Every year, ... or insufficient sleep and disease. Now there is a simple, ...
Cached Medicine News:Health News:MEDIA ALERT - Eularis to Hold Pharmaceutical Marketing ROI MasterClass in London 2Health News:Milliman Indicates 2009 Medical Cost for 'American family of four' Exceeds $16,700 Based on 7.4% Cost Increase 2Health News:Fate Therapeutics Adds Pratik Multani, M.D., M.S., as Vice President Clinical Development to Advance Upcoming Clinical Programs of Stem Cell Modulators 2Health News:Fate Therapeutics Adds Pratik Multani, M.D., M.S., as Vice President Clinical Development to Advance Upcoming Clinical Programs of Stem Cell Modulators 3Health News:Fate Therapeutics Adds Pratik Multani, M.D., M.S., as Vice President Clinical Development to Advance Upcoming Clinical Programs of Stem Cell Modulators 4Health News:New Methods Could Speed Production of Flu Vaccines 2Health News:7 out of 10 women too embarrassed to discuss vaginal dryness and pain with their physician 2Health News:QualityMetric Offers Way to Measure the Impact of Sleep Problems on Individuals and Groups 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: